

Curriculum Vitae

Michael Jeltsch
Supervisor for doctoral programme, Associate professor
Division of Pharmaceutical Biosciences
Helsinki Institute of Sustainability Science (HELSUS)
Helsinki One Health (HOH)
Drug Research Program
Doctoral Programme in Drug Research
Doctoral Programme in Integrative Life Science
Type of address: Postal address.
PL 56 (Viikinkaari 5 E)
00014
Finland
Type of address: Postal address.
Finland
Email: michael.jeltsch@helsinki.fi
Phone: +358294125514
Mobile: +358504486364



Qualifications

Protein Chemistry, Docent, University of Helsinki
21 Dec 2002 → 13 Dec 2011
Award Date: 13 Dec 2011
Biochemistry, Ph.D., University of Helsinki
17 May 1997 → 20 Dec 2002
Award Date: 20 Dec 2002
Biochemistry, M.Sc., University of Helsinki
1995 → 16 May 1997
Award Date: 16 May 1997
Molecular Biology/Biochemistry, Vordiplom, University of Hamburg
1 Sept 1990 → 15 Oct 1992
Award Date: 15 Oct 1992
Baccalaureate, Gymnasium An Der Stenner, Iserlohn
4 Aug 1980 → 17 May 1989
Award Date: 17 May 1989

Principal Investigator

Period : 27.05.2013 - * in Medicum

Principal Investigator

Period : 01.08.2020 - * in Faculty of Pharmacy

Employment

Associate professor

Division of Pharmaceutical Biosciences
University of Helsinki
Finland
1 Aug 2020 → present

Helsinki Institute of Sustainability Science (HELSUS)

University of Helsinki
Helsingin yliopisto, Finland
30 May 2023 → present

Helsinki One Health (HOH)

University of Helsinki
HELSINGIN YLIOPISTO, Finland

9 Sept 2019 → present

Drug Research Program

University of Helsinki

Finland

1 Aug 2020 → present

Supervisor for doctoral programme

Doctoral Programme in Drug Research

University of Helsinki

Finland

1 Jan 2021 → present

Supervisor for doctoral programme

Doctoral Programme in Integrative Life Science

University of Helsinki

Finland

1 Jan 2021 → present

Postdoctoral Research Fellow

Wihuri Research Institute

Finland

1 Jan 2013 → 31 Aug 2013

Contract Researcher

Vegenics Limited

1 Feb 2007 → 1 Dec 2011

Researcher

Lymphatix Oy

Finland

1 Apr 2006 → 1 Jan 2007

Contract Researcher

Licentia Ltd

1 Dec 1999 → 1 Dec 2005

Research Assistant

Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol

Germany

1 Jan 1994 → 1 Jan 1995

Publications

Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase

Niemelä, A., Giorgi, L., Nouri, S., Yurttas, B., Rauniyar, K., Jeltsch, M. & Koivuniemi, A., Dec 2024, In: Scientific Reports. 14, 1, 26085.

Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid-Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy

López-Cerdá, S., Molinaro, G., Pareja Tello, R., Rebelo Correia, A. M., König, S., Steinberger, P., Jeltsch, M., Hirvonen, J. T., Barreto, G., Stöckl, J. & Santos, H. A., 2024, In: ACS Applied Materials & Interfaces. 16, 15, p. 18643–18657 15 p.

The relationship between the secondary vascular system and the lymphatic vascular system in fish

Panara, V., Varaliová, Z., Wilting, J., Koltowska, K. & Jeltsch, M., 2024, In: *Biological Reviews*. 99, 6, p. 2108-2133 26 p.

Expansion and collapse of VEGF diversity in major clades of the animal kingdom

Rauniyar, K., Bokharaie, H. & Jeltsch, M., Aug 2023, In: *Angiogenesis*. 26, 3, p. 437-461 25 p.

Bioactive VEGF-C from *E. coli*

Rauniyar, K., Akhondzadeh, S., Gaciarz, A., Künnapuu, J. & Jeltsch, M., 28 Oct 2022, In: *Scientific Reports*. 12, 1, 16 p., 18157.

Lymphatic-to-blood vessel transdifferentiation in zebrafish

Jeltsch, M. & Alitalo, K., 25 May 2022, In: *Nature Cardiovascular Research*. 1, p. 539-541 3 p.

KLK3 in the Regulation of Angiogenesis—Tumorigenic or Not?

Koistinen, H., Künnapuu-Vulli, J. & Jeltsch, M., 17 Dec 2021, In: *International Journal of Molecular Sciences*. 22, 24, 14 p., 13545.

Outside in and brakes off for lymphatic growth

Künnapuu-Vulli, J. & Jeltsch, M., 10 Aug 2021, In: *Science signaling*. 14, 695, 2 p., 5058.

Proteolytic Cleavages in the VEGF Family: Generating Diversity among Angiogenic VEGFs, Essential for the Activation of Lymphangiogenic VEGFs

Künnapuu, J., Bokharaie, H. & Jeltsch, M., Feb 2021, In: *Biology*. 10, 2, 23 p., 167.

VEGF-C protects the integrity of the bone marrow perivascular niche in mice

Fang, S., Chen, S., Nurmi, H., Leppänen, V.-M., Jeltsch, M., Scadden, D. T., Silberstein, L., Mikkola, H. & Alitalo, K., 15 Oct 2020, In: *Blood*. 136, 16, p. 1871–1883 13 p.

Investigation on the role of biallelic variants in VEGF-C found in a patient affected by Milroy-like lymphedema

Mukenge, S., Jha, S. K., Catena, M., Manara, E., Leppänen, V.-M., Lenti, E., Negrini, D., Bertelli, M., Brendolan, A., Jeltsch, M. & Aldrighetti, L., Sept 2020, In: *Molecular Genetics & Genomic Medicine*. 8, 9, 10 p., 1389.

Imusuonet ja silmä

Gucciardo, E., Lehti, T. A., Korhonen, A., Salven, P., Lehti, K., Jeltsch, M. & Loukovaara, S., 26 Aug 2020, In: *Duodecim*. 136, 16, p. 1777-1788 12 p.

Die proteolytische Aktivierung des Vaskulären Endothelzellwachstumsfaktors-C

Lackner, M., Schmotz, C. & Jeltsch, M., 18 Dec 2019, In: *Lymphologie in Forschung und Praxis*. 23, 2, p. 88 98 p.

KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D

Jha, S. K., Rauniyar, K., Chronowska, E., Mattonet, K., Maina, E., Koistinen, H., Stenman, U. H., Alitalo, K. & Jeltsch, M., 17 May 2019, In: *eLife*. 8, 30 p., 44478.

Was man in der Lymphologie über VEGF-C wissen sollte

Jeltsch, M., 1 Jul 2018, In: *Vasomed : die Fachzeitschrift für Gefäßerkrankungen*. 30, 4, p. 172-173 2 p.

Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels

Rauniyar, K., Jha, S. K. & Jeltsch, M. M., 12 Feb 2018, In: *Frontiers in Bioengineering and Biotechnology*. 6, 12 p., 7.

Key molecules in lymphatic development, function, and identification

Jha, S. K., Rauniyar, K. & Jeltsch, M., 2018, In: *Annals of Anatomy*. 219, p. 25-34 10 p.

Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1

Jha, S. K., Rauniyar, K., Kärpänen, T., Leppänen, V.-M., Brouillard, P., Vikkula, M., Alitalo, K. & Jeltsch, M., 7 Jul 2017, In: *Scientific Reports*. 7, 13 p., 4916.

Factors regulating the substrate specificity of cytosolic phospholipase A(2)-alpha in vitro

Batchu, K. C., Hänninen, S., Jha, S. K., Jeltsch, M. & Somerharju, P., Nov 2016, In: *Biochimica and Biophysica Acta. Molecular and Cell Biology of Lipids*. 1861, 11, p. 1597-1604 8 p.

Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis

Johns, S. C., Yin, X., Jeltsch, M., Bishop, J. R., Schuksz, M., El Ghazal, R., Wilcox-Adelman, S. A., Alitalo, K. & Fuster, M. M., 8 Jul 2016, In: *Circulation Research*. 119, 2, p. 210-+ 24 p.

From Molecular Genetics and Biology to Effective Treatments of Lymphatic Disorders

Jeltsch, M., 13 May 2016, *The European Journal of Lymphology and Related Problems*. Vol. 28. p. 11 1 p.

Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts

Dashkevich, A., Raissadati, A., Syrjala, S. O., Zarkada, G., Keranen, M. A. I., Tuuminen, R., Krebs, R., Anisimov, A., Jeltsch, M., Leppanen, V.-M., Alitalo, K., Nykanen, A. I. & Lemstrom, K. B., Apr 2016, In: *American Journal of Transplantation*. 16, 4, p. 1160-1172 13 p.

Lymphatic Vessels in Regenerative Medicine and Tissue Engineering

Schaupper, M., Jeltsch, M., Rohringer, S., Redl, H. & Holthöner, W., 2016, In: *Tissue Engineering. Part B. Reviews*. 22, 5, p. 395-407 13 p.

Methods and uses related to ADAMTS3

Alitalo, K., Jeltsch, M., Jha, S. K. & Tvorogov, D., 30 Jul 2015, WIPO, Patent No. WO2015/110707, 30 Jul 2015, Priority date 24 Jan 2014, Priority No. 20145073 (FI)

Lymphangiogenesis in Health and Disease

Jeltsch, M., 13 May 2015, *The European Journal of Lymphology and Related Problems*. Vol. 26. p. 8 1 p.

Functional Dissection of the CCBE1 Protein A Crucial Requirement for the Collagen Repeat Domain

Roukens, M. G., Peterson-Maduro, J., Padberg, Y., Jeltsch, M., Leppanen, V.-M., Bos, F. L., Alitalo, K., Schulte-Merker, S. & Schulte, D., 8 May 2015, In: *Circulation Research*. 116, 10, p. 1660-U153 22 p.

Substrate Efflux Propensity Is the Key Determinant of Ca²⁺-independent Phospholipase A-beta (iPLA beta)-mediated Glycerophospholipid Hydrolysis

Batchu, K. C., Hokynar, K., Jeltsch, M., Somerharju, P. & Mattonet, K., 17 Apr 2015, In: *Journal of Biological Chemistry*. 290, 16, p. 10093-10103 11 p.

Therapeutic use of VEGF-C and CCBE1

Alitalo, K., Jeltsch, M. & Anisimov, A., 19 Feb 2015, WIPO, Patent No. WO2015/022447, 15 Feb 2015, Priority date 14 Aug 2013, Priority No. 20135832 (FI)

Die genetischen Ursachen des primären Lymphödems: Erkrankungen des Lymphgefäßsystems

Wiltling, J., Jeltsch, M. & Mattonet, K., 2015, *Erkrankungen des Lymphgefäßsystems*. Weissleder, H. & Schuchhardt, C. (eds.). 6 ed. Cologne: Viavital Verlag, p. 210-229 20 p.

The TIE Receptor Family

Saharinen, P. I., Jeltsch, M. M., Santoyo, M. M., Leppänen, V.-M. & Alitalo, K. K., 2015, *Receptor Tyrosine Kinases: Family and Subfamilies*. Wheeler, D. L. & Yarden, Y. (eds.). Springer-Verlag, p. 743-775 33 p.

Über die heterogene Herkunft des Lymphgefäßsystems

Jeltsch, M. M. & Mattonet, K., 2015, In: *Lymphologie in Forschung und Praxis*. 19, 2, p. 84-88 5 p.

CCBE1 Enhances Lymphangiogenesis via A Disintegrin and Metalloprotease With Thrombospondin Motifs-3-Mediated Vascular Endothelial Growth Factor-C Activation

Jeltsch, M., Jha, S. K., Tvorogov, D., Anisimov, A., Leppanen, V.-M., Holopainen, T., Kivela, R., Ortega, S., Karpanen, T. & Alitalo, K., 13 May 2014, In: *Circulation* . 129, 19, p. 1962-1971 10 p.

Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D: Teil 2: Die Rolle von VEGF-C und VEGF-D bei Krankheiten des Lymphgefäßsystems

Jeltsch, M., Lackner, M. & Krebs, R., 1 Feb 2014, In: *Vasomed : die Fachzeitschrift für Gefäßerkrankungen*. 26, 1, p. 48-50 3 p.

Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D: Teil 1: Grundlagen und Embryonalentwicklung

Jeltsch, M. & Krebs, R., 1 Dec 2013, In: *Vasomed : die Fachzeitschrift für Gefäßerkrankungen*. 25, 6, p. 335-336 2 p.

Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D. Teil 2. Die Rolle von VEGF-C und VEGF-D bei Krankheiten des Lymphgefäßsystems

Krebs, R. & Jeltsch, M., 1 Dec 2013, In: *Lymphologie in Forschung und Praxis*. 17, 2, p. 96-104 9 p.

Receptor Tyrosine Kinase-Mediated Angiogenesis

Jeltsch, M., Leppänen, V.-M., Saharinen, P. & Alitalo, K., Sept 2013, In: *Cold Spring Harbor Perspectives in Biology*. 5, 9, p. Article Number: a009183 22 p.

Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation

Leppänen, V.-M., Tvorogov, D., Kisko, K., Protá, A. E., Jeltsch, M., Anisimov, A., Markovic-Mueller, S., Stutfeld, E., Goldie, K. N., Ballmer-Hofer, K. & Alitalo, K., 6 Aug 2013, In: *Proceedings of the National Academy of Sciences of the United States of America*. 110, 32, p. 12960-12965 6 p.

The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands

Anisimov, A., Leppanen, V.-M., Tvorogov, D., Zarkada, G., Jeltsch, M., Holopainen, T., Kaijalainen, S. & Alitalo, K., 2 Jul 2013, In: *Science signaling*. 6, 282, p. ra52 10 p.

Use of VEGF-D gene to prevent restenosis

Alitalo, K. K., Ylä-Herttua, S., Hiltunen, M., Jeltsch, M. M. & Achen, M. G., 4 Jun 2013, US Patent and Trademark Office, Patent No. US 8,455,453 B2, 4 Jun 2013, Priority date 26 Oct 1998, Priority No. 60/105,587

Die lymphangiogenen Wachstumsfaktoren VEGF-C und VEGF-D: Teil 1: Grundlagen und Embryonalentwicklung

Krebs, R. & Jeltsch, M., 1 Jun 2013, In: *Lymphologie in Forschung und Praxis*. 17, 1, p. 30-37 8 p.

A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development

Villefranc, J. A., Nicoli, S., Bentley, K., Jeltsch, M., Zarkada, G., Moore, J. C., Gerhardt, H., Alitalo, K. & Lawson, N. D., 1 Apr 2013, In: *Development*. 140, 7, p. 1497-1506 10 p.

Vascular Endothelial Growth Factor-Angiopoietin Chimera With Improved Properties for Therapeutic Angiogenesis

Anisimov, A., Tvorogov, D., Alitalo, A., Leppänen, V.-M., An, Y., Han, E. C., Orsenigo, F., Gaal, E. I., Holopainen, T., Koh, Y. J., Tammela, T., Korpisalo, P., Keskitalo, S., Jeltsch, M., Ylä-Herttua, S., Dejana, E., Koh, G. Y., Choi, C., Saharinen, P. & Alitalo, K., 2013, In: *Circulation* . 127, 4, p. 424-434 11 p.

Critical Role of VEGF-C/VEGFR-3 Signaling in Innate and Adaptive Immune Responses in Experimental Obliterative Bronchiolitis

Krebs, R., Tikkanen, J. M., Ropponen, J. O., Jeltsch, M., Jokinen, J. J., Ylä-Herttua, S., Nykanen, A. I. & Lemstrom, K. B., Nov 2012, In: *The American Journal of Pathology*. 181, 5, p. 1607-1620 14 p.

Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins

Alitalo, K. K. & Jeltsch, M., 2 Oct 2012, US Patent and Trademark Office, Patent No. US 8,278,098 B2, 2 Oct 2012, Priority date 25 Feb 2000, Priority No. 60/185,205

VEGFR-2-specific forms of VEGF-D and VEGF-C and uses thereof

Alitalo, K. K., Jeltsch, M. M., Leppänen, V.-M., Aho, K. K., Anisimov, A. & Tvorogov, D., 5 Jul 2012, WIPO, Patent No. WO2012/088563, 2 Jul 2012, Priority date 24 Nov 2010, Priority No. 61/458,517 (US)

Modified VEGF-A with improved angiogenic properties

Alitalo, K. K., Tammela, T. L. H., Keskitalo, S. E., Pajusola, K. M., Jeltsch, M. M., Ylä-Herttuala, S., Kärpänen, T. H., Eriksson, U. & Uutela, M. J. T., 27 Sept 2011, US Patent and Trademark Office, Patent No. US 8,025,886 B2, 27 Sept 2011, Priority date 15 Aug 2005, Priority No. 60/708,226

Structural determinants of vascular endothelial growth factor-D receptor binding and specificity

Leppänen, V.-M., Jeltsch, M., Anisimov, A., Tvorogov, D., Aho, K., Kalkkinen, N., Toivanen, P., Ylä-Herttuala, S., Ballmer-Hofer, K. & Alitalo, K., 2011, In: *Blood*. 117, 5, p. 1507-1515 9 p.

Growth factor binding constructs, materials and methods

Alitalo, K. K. & Jeltsch, M. M., 21 Dec 2010, US Patent and Trademark Office, Patent No. US 7,855,178 B2, 21 Dec 2010, Priority date 5 Mar 2004, Priority No. 60/550,907

Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development

Saharinen, P. I., Heloterä, H., Miettinen, J., Norrmen, C., D Amico Lago, G. V., Jeltsch, M., Langenberg, T., Vandevelde, W., Ny, A., Dewerchin, M., Carmeliet, P. & Alitalo, K., 2010, In: *Genes & Development*. 24, 9, p. 875-880 6 p.

Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization

Tvorogov, D., Anisimov, A., Zheng, W., Leppänen, V.-M., Tammela, T., Laurinavicius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., Kalkkinen, N., Lankinen, H., Ojala, P. M. & Alitalo, K., 2010, In: *Cancer Cell*. 18, 6, p. 630-640 11 p.

Structural determinants of growth factor binding and specificity by VEGF receptor 2

Leppänen, V.-M., Prota, A. E., Jeltsch, M., Anisimov, A., Kalkkinen, N., Strandin, T., Lankinen, H., Goldman, A., Ballmer-Hofer, K. & Alitalo, K., 2010, In: *Proceedings of the National Academy of Sciences of the United States of America*. 107, 6, p. 2425-2430 6 p.

Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis

Albrecht, I., Kopfstein, L., Strittmatter, K., Schomber, T., Falkevall, A., Hagberg, C. E., Lorentz, P., Jeltsch, M., Alitalo, K., Eriksson, U., Christofori, G. & Pietras, K., 2010, In: *PLoS One*. 5, 11, p. Article Number: e14109 13 p.

Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation

Bry, M., Kivelä, R., Holopainen, T., Anisimov, A., Tammela, T., Soronen, J., Silvola, J., Saraste, A., Jeltsch, M., Korpisalo, P., Carmeliet, P., Lemström, K. B., Shibuya, M., Ylä-Herttuala, S., Alhonen, L., Mervaala, E., Andersson, L. C., Knuuti, J. & Alitalo, K., 2010, In: *Circulation*. 122, 17, p. 1725-1733 9 p.

Activated Forms of VEGF-C and VEGF-D Provide Improved Vascular Function in Skeletal Muscle

Anisimov, A., Alitalo, A., Korpisalo, P., Soronen, J., Kaijalainen, S., Leppänen, V.-M., Jeltsch, M., Ylä-Herttuala, S. & Alitalo, K., 2009, In: *Circulation Research*. 104, p. 1302-U156 25 p.

VEGFR-3 fusion proteins

Alitalo, K. K. & Jeltsch, M. M., 9 Sept 2008, US Patent and Trademark Office, Patent No. US 7,422,741 B2, 9 Sept 2008, Priority date 5 Mar 2004, Priority No. 60/550,907

Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy

Kärpänen, T., Bry, M., Ollila, H., Seppänen-Laakso, T., Liimatta, E., Leskinen, H., Kivelä, R., Helkamaa, T., Merentie, M., Jeltsch, M., Paavonen, K., Andersson, L. C., Mervaala, E., Hassinen, I., Ylä-Herttuala, S., Oresic, M. & Alitalo, K., 2008, In: *Circulation Research*. 103, 9, p. 1018-1026 9 p.

Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium

Li, X., Tjwa, M., Van Hove, I., Enholm, B., Neven, E., Paavonen, K., Jeltsch, M., Juan, T. D., Sievers, R. E., Chorianopoulos, E., Wada, H., Vanwildemeersch, M., Noel, A., Foidart, J.-M., Springer, M. L., von Degenfeld, G., Dewerchin, M., Blau, H. M., Alitalo, K. & Eriksson, U. & 2 others, Carmeliet, P. & Moons, L., 2008, In: *Arteriosclerosis, Thrombosis, and Vascular Biology*. 28, 9, p. 1614-1620 7 p.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

Heckman, C. A., Holopainen, T., Wirzenius, M., Keskitalo, S., Jeltsch, M., Ylä-Herttuala, S., Wedge, S. R., Jurgensmeier, J. M. & Alitalo, K., 2008, In: *Cancer Research*. 68, 12, p. 4754-4762 9 p.

Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins

Tammela, T., He, Y., Lyytikä, J., Jeltsch, M., Markkanen, J., Pajusola, K., Ylä-Herttuala, S. & Alitalo, K., 2007, In: *Circulation Research*. 100, 10, p. 1468-1475 8 p.

Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein

Keskitalo, S., Tammela, T., Lyytikä, J., Kärpänen, T., Jeltsch, M., Markkanen, J., Ylä-Herttuala, S. & Alitalo, K., 2007, In: *Circulation Research*. 100, 10, p. 1460-1467 8 p.

Functional interaction of VEGF-C and VEGF-D with neuropilin receptors

Kärpänen, T., Heckman, C. A., Keskitalo, S., Jeltsch, M., Ollila, H., Neufeld, G., Tamagnone, L. & Alitalo, K., 2006, In: *FASEB Journal*. 20, 9, p. 1462-1472 1 p.

Sigma-RBI Handbook of Receptor Classification and Signal Transduction: VEGF Receptors

Jeltsch, M. & Alitalo, K., 2006, 5. ed. Natick, MA: Sigma-Aldrich Research Biotechnology, L.P. 3 p.

Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns

Jeltsch, M., Kärpänen, T., Strandin, T., Aho, K., Lankinen, H. & Alitalo, K., 2006, In: *Journal of Biological Chemistry*. 281, 17, p. 12187-12195 9 p.

Use of VEGF-C to prevent restenosis

Alitalo, K. K., Ylä-Herttuala, S., Hiltunen, M., Jeltsch, M. M. & Achen, M. G., 25 Oct 2005, US Patent and Trademark Office, Patent No. US 6,958,147 B1, 25 Oct 2005, Priority date 26 Oct 1998, Priority No. 60/105,587

Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis

Krebs, R., Tikkanen, J. M., Nykänen, A. I., Wood, J., Jeltsch, M., Ylä-Herttuala, S., Koskinen, P. K. & Lemström, K., 2005, In: *American Journal of Respiratory and Critical Care Medicine*. 171, 12, p. 1421-1429 9 p.

Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation

Baluk, P., Tammela, T., Ator, E., Lyubynska, N., Achen, M. G., Hicklin, D. J., Jeltsch, M., Petrova, T., Pytowski, B., Stacker, S. A., Ylä-Herttuala, S., Jackson, D. G., Alitalo, K. & McDonald, D. M., 2005, In: *Journal of Clinical Investigation*. 115, 2, p. 247-257 11 p.

Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels

He, Y., Rajantie, I., Pajusola, K., Jeltsch, M., Holopainen, T. T., Ylä-Herttuala, S., Harding, T., Jooss, K., Takahashi, T. & Alitalo, K., 2005, In: *Cancer Research*. 65, 11, p. 4739-4746 8 p.

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

Kärkkäinen, M. J., Haiko, P., Sainio, K. M. H., Partanen, J. M., Taipale, J., Petrova, T. V., Jeltsch, M., Jackson, D. G., Talikka, M., Rauvala, H., Betsholtz, C. & Alitalo, K., 2004, In: *Nature immunology*. 5, 1, p. 74-80 7 p.

Genesis and pathogenesis of lymphatic vessels

Jeltsch, M., Tammela, T., Alitalo, K. & Wilting, J., 2003, In: Cell and Tissue Research. 314, p. 69-84 16 p.

Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function

Veikkola, T., Lohela, M., Ikenberg, K., Makinen, T., Korff, T., Saaristo, A., Petrova, T., Jeltsch, M., Augustin, H. G. & Alitalo, K., 2003, In: FASEB Journal. 17, p. 2006-2013 8 p.

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia

Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D. & Betsholtz, C., 2003, In: Journal of Cell Biology. 161, p. 1163-1177 15 p.

Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B: patent application

Jeltsch, M. M., Alitalo, K. K., Olofsson, B. & Eriksson, U., 6 Jun 2002, US Patent and Trademark Office, Patent No. US 2001/0068694 A1, 6 Jun 2002, Priority date 26 Jun 2000, Priority No. 60/220,824

Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes

Saaristo, A., Veikkola, T., Enholm, B., Hytonen, M., Arola, J., Pajusola, K., Turunen, P., Jeltsch, M., Karkkainen, M. J., Kerjaschki, D., Bueler, H., Yla-Herttuala, S. & Alitalo, K., 2002, In: FASEB Journal. 16, p. 1041-1049 9 p.

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

Veikkola, T. M., Jussila, L., Mäkinen, T. M., Kärpänen, T. H., Jeltsch, M., Petrova, T., Hajime, K., Hajime, K., Gavin, T., McDonald, D. M., Marc G, A., Stackner, S. A. & Alitalo, K., 15 Mar 2001, In: EMBO Journal. 20, 6, p. 1223-1231 9 p.

Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin

Enholm, B., Karpanen, T., Jeltsch, M., Kubo, H., Stenback, F., Prevo, R., Jackson, D. G., Yla-Herttuala, S. & Alitalo, K., 2001, In: Circulation Research. 88, p. 623-629 7 p.

Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice.

Jussila, L., Veikkola, T., Jeltsch, M., Thurston, G., McDonald, D., Achen, M., Stackner, S. & Alitalo, K., 2001, In: Clinical Cancer Research. 7, p. 3762S-3762S 1 p.

Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis

Mandriota, S. J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G., Orci, L., Alitalo, K., Christofori, G. & Pepper, M. S., 2001, In: EMBO Journal. 20, p. 672-682 11 p.

VEGF-C adenovirus gene transfer reduces intima formation in rabbits

Jeltsch, M., Hiltunen, M. O., Laitinen, M., Turunen, M. P., Hartikainen, J., Rissanen, T. T., Laukkanen, J., Niemi, M., Kossila, M., Häkkinen, T. P., Kivela, A., Enholm, B. C., Mansukoski, H., Turunen, A.-M., Alitalo, K. & Ylä-Herttala, S., Jul 2000, 1 ed. 1 p. (Atherosclerosis; vol. 151, no. 1)

Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta

Hiltunen, M. O., Laitinen, M., Turunen, M. P., Jeltsch, M., Hartikainen, J., Rissanen, T. T., Laukkanen, J., Niemi, M., Kossila, M., Hakkinen, T. P., Kivela, A., Enholm, B., Mansukoski, H., Turunen, A. M., Alitalo, K. & Yla-Herttuala, S., 2000, In: Circulation . 102, p. 2262-2268 7 p.

Current biology of VEGF-B and VEGF-C

Olofsson, B., Jeltsch, M., Eriksson, U. & Alitalo, K., 1999, In: Current Opinion in Biotechnology. 1999/10, 6, p. 528-535 8 p.

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

Olofsson, B., Korpelainen, E., Pepper, M. S., Mandriota, S. J., Aase, K., Kumar, V., Gunji, Y., Jeltsch, M., Shibuya, M., Alitalo, K. & Eriksson, U., 29 Sept 1998, In: Proceedings of the National Academy of Sciences of the United States of America. 1998/95, 20, p. 11709-11714 6 p.

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

Achen, M. G., Jeltsch, M., Kukk, E., Makinen, T., Vitali, A., Wilks, A. F., Alitalo, K. & Stacker, S. A., 1998, In: Proceedings of the National Academy of Sciences of the United States of America. 95, p. 548-553 6 p.

Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity

Pepper, M. S., Mandriota, S. J., Jeltsch, M., Kumar, V. & Alitalo, K., 1998, In: Journal of Cellular Physiology. 177, p. 439-452 14 p.

Genomic organization of human and mouse genes for vascular endothelial growth factor C

Chilov, D., Kukk, E., Taira, S., Jeltsch, M., Kaukonen, J., Palotie, A., Joukov, V. & Alitalo, K., 1997, In: Journal of Biological Chemistry. 272, p. 25176-25183 8 p.

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X. J., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K. & Alitalo, K., 1997, In: Science. 276, p. 1423-1425 3 p.

Proteolytic processing regulates receptor specificity and activity of VEGF-C

Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., ClaessonWelsh, L., Cao, Y. H., Saksela, O., Kalkkinen, N. & Alitalo, K., 1997, In: EMBO Journal. 16, p. 3898-3911 14 p.

Vascular endothelial growth factors VEGF-B and VEGF-C

Joukov, V., Kaipainen, A., Jeltsch, M., Pajusola, K., Olofsson, B., Kumar, V., Eriksson, U. & Alitalo, K., 1997, In: Journal of Cellular Physiology. 1997/173, p. 211-215 5 p.

VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane

Oh, S. J., Jeltsch, M. M., Birkenhager, R., McCarthy, J. E. G., Weich, H. A., Christ, B., Alitalo, K. & Wiltling, J., 1997, In: Developmental Biology. 188, p. 96-109 14 p.

VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development

Kukk, E., Lymboussaki, A., Taira, S., Kaipainen, A., Jeltsch, M., Joukov, V. & Alitalo, K., 1996, In: Sustainable Development. 122, p. 3829-3837 9 p.

Prizes

Circulation's Best Paper Award 2015: Category "Basic Science"

Jeltsch, M. (Recipient), 8 Nov 2015

Innoopeli Prize 2022

Hanski, L. (Recipient), Airavaara, M. (Recipient), Bunker, A. E. (Recipient), Holmström, A.-R. (Recipient), Jeltsch, M. (Recipient), Rantamäki, T. (Recipient), Sikanen, T. (Recipient), Voutilainen, M. (Recipient), Lindstedt, H. P. (Recipient), Kuusinen, A. (Recipient), Haapalainen, J. T. V. (Recipient), Hintikka, S. J. (Recipient), Baramaki, I. (Recipient) & Kaukiainen, K. (Recipient), 9 Dec 2022

Mandatum Ph.D. Thesis Prize 2003

Jeltsch, M. (Recipient), 24 Mar 2003

Medix Prize of the Minerva Foundation 1998: Best biomedical publication of the year from Finland

Jeltsch, M. (Recipient), 17 Sept 1998

Medix Prize of the Minerva Foundation 2004

Jeltsch, M. (Recipient), 22 Sept 2004

Medix Prize of the Minerva Foundation 2011

Jeltsch, M. (Recipient), 12 Sept 2011

TUKOKE

Bask, P. (Recipient), Siljander, O. (Recipient), Rasmus, P. (Recipient), Koppatz, N. (Recipient) & Jeltsch, M. (Recipient),
23 Apr 2021